Research study Program year 2021 Source: CMS Open Payments

Phase 2b - Dose and Regimen Finding Study

Research payments

$2,753,701

50 payments

Through program year 2021, $2,753,701 in research payments was reported against Phase 2b - Dose and Regimen Finding Study, across 50 payments, paid by Amgen Inc..

Paid by: Amgen Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

2 rows

Year	Kind	Amount	Payments
2021	Research	$2,173,930	25
2020	Research	$579,771	25

Breakdown

Who paid Research payments · program years 2020–2021

Amgen Inc. $2,753,701 50 payments

Who received the money Research payments · program years 2020–2021

Mount Sinai Hospital Organisation paid for research $480,311 4 payments
Westside Medical Associates Of Los Angeles Organisation paid for research $396,831 5 payments
Brigham And Womens Hospital Teaching hospital · MA $395,049 3 payments
Excel Medical Clinical Trials Organisation paid for research $324,008 3 payments
Johns Hopkins Organisation paid for research $259,189 4 payments
Crossroads Clinical Research INC Organisation paid for research $242,028 4 payments
Columbia University Medical Center Organisation paid for research $186,701 4 payments
Baylor College Of Medicine Organisation paid for research $142,803 5 payments
University Of Kansas Medical Center Organisation paid for research $140,094 4 payments
Cleveland Clinic Organisation paid for research $73,116 4 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

7 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.